The Role of Qatar Community Pharmacists in Depression care: A Survey of Attitudes, Practices and Perceived Barriers

Rula Shami¹, Mohammed Fasihul Alam¹, Maguy El Haji²
¹College of Health Sciences, Public health Department, Qatar University, Doha, Qatar ²College of Pharmacy, Qatar University, Doha, Qatar

Background and Objective

• Depression is a main contributor to mortality and exacerbation of other health problems [1], and one of the leading causes of disability in the world [2]. Negative attitudes and stigma remain to be major barriers to healthcare provision and access to treatment for patients with depression.

• Up to 33% of patients who have depression prematurely discontinue treatment within the first 30 days, and 40 % of them within 90 days of antidepressant initiation [3].

• Community pharmacists play an important role in the care of major depression, being among the most accessible healthcare providers who can enhance patients’ adherence to antidepressant regimens through antidepressant medication counselling and management [4].

• Currently Qatar has around 1200 community pharmacists, but little is known whether they are sufficiently contributing to depression care.

• Our study aims to describe the current practices, attitudes and perceived barriers of Qatar community pharmacists towards the provision of depression care, and to investigate how pharmacists’ attitudes, along with several sociodemographic and professional characteristics, are associated with these practices.

Methodology

• A cross-sectional online survey targeting all practicing community pharmacists based on an updated contact list of practicing from Qatar Ministry of Public Health (MoPH) and using an adapted survey instrument.

• Study outcomes were:
  ➢ scores of attitudes towards depression
  ➢ scores of self-reported depression care practices
  ➢ perceived barriers for depression care

• Responses were measured on a 5-point-Likert scale.

• Descriptive univariate and bivariate analyses of study outcomes were conducted, along with a multivariate regression, to investigate how pharmacists’ characteristics and attitudes affect their practice.

• Data was analyzed using STATA15.1 software.

Results: Pharmacists’ Practices

Results: Pharmacists’ Attitudes

Pharmacists who reported that they “usually” or “always”:

Screen patients for major depression or other mental illness  11.4%
Contact patients’ physician to adjust the prescribed antidepressant regimen (change dose, remove or add additional medications)  13.9%
Follow up patients who have major depression.  13.9%
Provide written information/handout/guide about major depression and/or about the prescribed antidepressant drug regimen  17.6%
Provide information about symptoms and/or causes of major depression.  22.0%
Provide verbal information about major depression and/or about the prescribed antidepressant drug regimen  23.6%
Ask patients about potential barriers to taking the antidepressant(s) prescribed.  28.0%
Discuss options for managing possible side effects of antidepressant medication.  29.8%
Refer patients to trusted mental health care practitioners in the community  31.2%
Provide information about the purpose of the antidepressant medication  33.6%
Provide information about the time course of response to antidepressant medication.  33.65%
Encourage adherence to the antidepressant regimen  37.9%

Results: Pharmacists’ Perceived Barriers

Results: Factors associated with pharmacists’ practices

• Female pharmacists were significantly less involved in depression care compared to male pharmacists (Beta-coefficient= -4.36, 95% CI -7.46 to -1.26, p<0.01).

• The presence of a private area for counselling patients was associated with higher scores of practice (Beta-coefficient=-3.39, 95% CI 0.20 to 6.59 p = 0.03).

• Depression practice score increased with an increasing score of attitudes (Beta-coefficient=0.22, 95% CI 0.09 to 0.35, p= 0.001), and decreased with the number of years since the last pharmacy degree graduation (p=0.02).

Conclusion

• Pharmacists’ moderately positive attitudes towards depression and its care were not reflected in their current practices. Such results could be explained by the presence of a set of perceived barriers that were identified in this study, such as the lack of needed knowledge and the lack of a private consultation area in the pharmacy.

• Study results imply a need for the development of depression care training programs that are directed to improve pharmacists’ knowledge on depression and to reduce pharmacists’ stigma towards patients who suffer from depression.

• Results from this study may also serve as a baseline for future local longitudinal studies addressed towards improving the provision of care for depression as a major public health issue in Qatar.

References


4. WHO. The Role of the Pharmacist in the Health Care System: PART II. 2014